Navigation Links
AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Date:8/24/2007

MINNEAPOLIS, Aug. 24 /PRNewswire/ -- AGA Medical Corporation ("AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II").

The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood vessel malformations in the peripheral vasculature. The Amplatzer Vascular Plug II is a self- expandable nitinol mesh occlusion device and is designed to be introduced in a minimally invasive fashion through a catheter. The delivery cable that comes pre-attached uses the unique AMPLATZER user interface to enable the physician to more precisely position the device in the targeted blood vessel. Once positioned, the cable is unscrewed and the device is released. The vascular plug II is designed with multiple lobes to facilitate rapid clotting.

"I have used the new Amplatzer Vascular Plug and I found it to be very easy to use and very effective in causing a quick and complete occlusion, said Dr. James F. Benenati, Medical Director of the Peripheral Vascular Lab at the Baptist Cardiac & Vascular Institute in Miami, Florida. "Deployment is easy, radio-opacity is excellent and occlusion is complete and rapid."

The vascular plug two comes in sizes ranging from 3 mm to 22 mm enabling treatment of a wider range of vessel sizes. Unlike competing devices, a single vascular plug II is generally required to occlude the targeted vessel making it a cost and time effective alternative.

"The new vascular plug is an important addition to our family of occlusion devices", said Franck Gougeon, President and CEO of AGA. "The vascular plug is among the fastest growing AGA products and we believe this new model can only help to further accelerate its growth. With more products under development that are specifically targeted for use by interventional specialists that treat peripheral vascular disease, the vascular plug is establishing a strong and exciting foundation for future diversification by AGA Medical."

ABOUT AGA MEDICAL: AGA Medical Corporation, based in Plymouth, Minnesota (just outside Minneapolis) is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the Company has developed and commercializes a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart" such as atrial septal and patent foramen ovale defects. The company is expanding into new areas such as the minimally invasive repair of vascular abnormalities. Over 700 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices including improved patient outcomes, reduced length of stay and accelerated recovery times for the patient, AGA Medical devices have received regulatory approval and are marketed in over 90 countries with over 250,000 devices shipped to date. For more information visit http://www.amplatzer.com

MEDIA CONTACT:

Devin Nagy

Brunswick Group LLC

202.393.7337

dnagy@brunswickgroup.com


'/>"/>
SOURCE AGA Medical Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... In response ... treating gait disorders, Biodex Medical Systems, Inc. announces the release of their Gait Trainer ... has been joined with a biomedical system to aid in rehabilitating individuals with cerebral ...
(Date:5/18/2017)... ... 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners II ... grow. CSM has doubled in size over the past six months with the ... , Roger Gasper joins CSM as Chief Financial Officer. Roger has over 25 ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, is honored that Jay Crowley was ... in Brussels, Belgium. , Crowley played a crucial role in the development of ...
(Date:5/18/2017)... ... ... notified earlier this year that his company Asymmetrex had been selected as one ... , he was not surprised as others might be. Sherley says, “I felt like ... was particularly meaningful. Our selection by The Silicon Review may seem odd ...
Breaking Biology Technology:
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOG´s multi-biometrics system.   Continue ... ...
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
Breaking Biology News(10 mins):